Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.69 |
| ▸ | ALK | Q9UM73 | 8/20 | 0.68 |
| ▸ | JAK2 | O60674 | 1/20 | 0.58 |
| ▸ | SRC | P12931 | 1/20 | 0.58 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.58 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.57 |
| ▸ | IGF1R | P08069 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL382126 | 0.84 | EGFR (0.70) | EGFRALKZAP70IGF1R | |
| SCHEMBL10205065 | 0.82 | ALK (0.64) | EGFRALKJAK2SRCTNK2 | |
| SCHEMBL21846989 | 0.82 | EGFR (1.00) | EGFRALK | |
| SCHEMBL382124 | 0.81 | ALK (0.81) | EGFRALKZAP70IGF1R | |
| SCHEMBL16752958 | 0.81 | ALK (1.00) | EGFRALK | |
| SCHEMBL26161575 | 0.80 | ALK (0.85) | EGFRALKIGF1RKCNH2 | |
| SCHEMBL21846999 | 0.80 | EGFR (1.00) | EGFRALK | |
| SCHEMBL18506895 | 0.79 | ALK (0.66) | EGFRALKJAK2IGF1RKCNH2 | |
| SCHEMBL30502344 | 0.79 | ALK (0.87) | EGFRALKIGF1RKCNH2 | |
| SCHEMBL29188606 | 0.78 | ALK (0.82) | EGFRALKIGF1RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660458-B1 | 2, 4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2012-01-25 | — | — | EP | disclosed |